Global Drugs for PrEP Market Research Report 2024

Publication ID:

PB510243355

Publication Date:

October 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Drugs for Pre-Exposure Prophylaxis (PrEP) are antiretroviral medications used to prevent HIV infection in individuals at high risk of exposure. These drugs work by blocking the replication of HIV in the body if exposure occurs, significantly reducing the risk of infection. Taken daily, PrEP can lower HIV transmission risk by up to 99%. PrEP is recommended for individuals at high risk, such as men who have sex with men (MSM), people with HIV-positive partners, or those who engage in high-risk sexual activities or injectable drug use. In addition to oral medications, long-acting injectable forms like cabotegravir are being developed and used to enhance adherence and accessibility.
The global Drugs for PrEP market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Drugs for PrEP is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Drugs for PrEP is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Drugs for PrEP include Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Drugs for PrEP, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for PrEP.
The Drugs for PrEP market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Drugs for PrEP market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for PrEP manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Segment by Type
Oral Drugs
Injections
Segment by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs for PrEP manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs for PrEP in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Drugs for PrEP Market Overview
1.1 Product Definition
1.2 Drugs for PrEP by Type
1.2.1 Global Drugs for PrEP Market Value Comparison by Type (2024-2030)
1.2.2 Oral Drugs
1.2.3 Injections
1.3 Drugs for PrEP by Application
1.3.1 Global Drugs for PrEP Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Drugs for PrEP Market Size Estimates and Forecasts
1.4.1 Global Drugs for PrEP Revenue 2019-2030
1.4.2 Global Drugs for PrEP Sales 2019-2030
1.4.3 Global Drugs for PrEP Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs for PrEP Market Competition by Manufacturers
2.1 Global Drugs for PrEP Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs for PrEP Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs for PrEP Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Drugs for PrEP, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for PrEP, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for PrEP, Product Type & Application
2.7 Global Key Manufacturers of Drugs for PrEP, Date of Enter into This Industry
2.8 Global Drugs for PrEP Market Competitive Situation and Trends
2.8.1 Global Drugs for PrEP Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Drugs for PrEP Players Market Share by Revenue
2.8.3 Global Drugs for PrEP Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for PrEP Market Scenario by Region
3.1 Global Drugs for PrEP Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs for PrEP Sales by Region: 2019-2030
3.2.1 Global Drugs for PrEP Sales by Region: 2019-2024
3.2.2 Global Drugs for PrEP Sales by Region: 2025-2030
3.3 Global Drugs for PrEP Revenue by Region: 2019-2030
3.3.1 Global Drugs for PrEP Revenue by Region: 2019-2024
3.3.2 Global Drugs for PrEP Revenue by Region: 2025-2030
3.4 North America Drugs for PrEP Market Facts & Figures by Country
3.4.1 North America Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs for PrEP Sales by Country (2019-2030)
3.4.3 North America Drugs for PrEP Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for PrEP Market Facts & Figures by Country
3.5.1 Europe Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs for PrEP Sales by Country (2019-2030)
3.5.3 Europe Drugs for PrEP Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for PrEP Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for PrEP Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs for PrEP Sales by Region (2019-2030)
3.6.3 Asia Pacific Drugs for PrEP Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for PrEP Market Facts & Figures by Country
3.7.1 Latin America Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs for PrEP Sales by Country (2019-2030)
3.7.3 Latin America Drugs for PrEP Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for PrEP Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs for PrEP Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs for PrEP Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for PrEP Sales by Type (2019-2030)
4.1.1 Global Drugs for PrEP Sales by Type (2019-2024)
4.1.2 Global Drugs for PrEP Sales by Type (2025-2030)
4.1.3 Global Drugs for PrEP Sales Market Share by Type (2019-2030)
4.2 Global Drugs for PrEP Revenue by Type (2019-2030)
4.2.1 Global Drugs for PrEP Revenue by Type (2019-2024)
4.2.2 Global Drugs for PrEP Revenue by Type (2025-2030)
4.2.3 Global Drugs for PrEP Revenue Market Share by Type (2019-2030)
4.3 Global Drugs for PrEP Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs for PrEP Sales by Application (2019-2030)
5.1.1 Global Drugs for PrEP Sales by Application (2019-2024)
5.1.2 Global Drugs for PrEP Sales by Application (2025-2030)
5.1.3 Global Drugs for PrEP Sales Market Share by Application (2019-2030)
5.2 Global Drugs for PrEP Revenue by Application (2019-2030)
5.2.1 Global Drugs for PrEP Revenue by Application (2019-2024)
5.2.2 Global Drugs for PrEP Revenue by Application (2025-2030)
5.2.3 Global Drugs for PrEP Revenue Market Share by Application (2019-2030)
5.3 Global Drugs for PrEP Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Sciences Drugs for PrEP Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.2.4 ViiV Healthcare Drugs for PrEP Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Teva
6.3.1 Teva Company Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Drugs for PrEP Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Amneal Pharmaceuticals
6.4.1 Amneal Pharmaceuticals Company Information
6.4.2 Amneal Pharmaceuticals Description and Business Overview
6.4.3 Amneal Pharmaceuticals Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amneal Pharmaceuticals Drugs for PrEP Product Portfolio
6.4.5 Amneal Pharmaceuticals Recent Developments/Updates
6.5 Aurobindo Pharma
6.5.1 Aurobindo Pharma Company Information
6.5.2 Aurobindo Pharma Description and Business Overview
6.5.3 Aurobindo Pharma Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Aurobindo Pharma Drugs for PrEP Product Portfolio
6.5.5 Aurobindo Pharma Recent Developments/Updates
6.6 Mylan
6.6.1 Mylan Company Information
6.6.2 Mylan Description and Business Overview
6.6.3 Mylan Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mylan Drugs for PrEP Product Portfolio
6.6.5 Mylan Recent Developments/Updates
6.7 Zydus
6.7.1 Zydus Company Information
6.7.2 Zydus Description and Business Overview
6.7.3 Zydus Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Zydus Drugs for PrEP Product Portfolio
6.7.5 Zydus Recent Developments/Updates
6.8 Qilu Pharmaceutical
6.8.1 Qilu Pharmaceutical Company Information
6.8.2 Qilu Pharmaceutical Description and Business Overview
6.8.3 Qilu Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Qilu Pharmaceutical Drugs for PrEP Product Portfolio
6.8.5 Qilu Pharmaceutical Recent Developments/Updates
6.9 Anhui Baker Biopharmaceutical
6.9.1 Anhui Baker Biopharmaceutical Company Information
6.9.2 Anhui Baker Biopharmaceutical Description and Business Overview
6.9.3 Anhui Baker Biopharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio
6.9.5 Anhui Baker Biopharmaceutical Recent Developments/Updates
6.10 Chengdu Brilliant Pharmaceutical
6.10.1 Chengdu Brilliant Pharmaceutical Company Information
6.10.2 Chengdu Brilliant Pharmaceutical Description and Business Overview
6.10.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio
6.10.5 Chengdu Brilliant Pharmaceutical Recent Developments/Updates
6.11 North China Pharmaceutical
6.11.1 North China Pharmaceutical Company Information
6.11.2 North China Pharmaceutical Description and Business Overview
6.11.3 North China Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.11.4 North China Pharmaceutical Drugs for PrEP Product Portfolio
6.11.5 North China Pharmaceutical Recent Developments/Updates
6.12 Chia Tai Tianqing Pharmaceutical
6.12.1 Chia Tai Tianqing Pharmaceutical Company Information
6.12.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.12.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio
6.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for PrEP Industry Chain Analysis
7.2 Drugs for PrEP Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for PrEP Production Mode & Process
7.4 Drugs for PrEP Sales and Marketing
7.4.1 Drugs for PrEP Sales Channels
7.4.2 Drugs for PrEP Distributors
7.5 Drugs for PrEP Customers
8 Drugs for PrEP Market Dynamics
8.1 Drugs for PrEP Industry Trends
8.2 Drugs for PrEP Market Drivers
8.3 Drugs for PrEP Market Challenges
8.4 Drugs for PrEP Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂